The modulation of Amyotrophic Lateral Sclerosis risk by Ataxin-2 intermediate polyglutamine expansions is a specific effect
Suzana Gispert(Goethe University Frankfurt), Georg Auburger(Unknown), Tim Becker(German Center for Neurodegenerative Diseases), Inga Liepelt(Hertie Institute for Clinical Brain Research), Alexander Kurz(Goethe University Frankfurt), Stefan Waibel(Universität Ulm), Olaf Rieß(University Children's Hospital Tübingen), Christof Geisen(German Red Cross), Peter Bauer(Centogene (Germany)), Aaron D. Gitler(Stanford Medicine), Peter M. Andersen(Umeå University), Markus Weber(University of St.Gallen), Daniela Berg(Christian-Albrechts-Universität zu Kiel), Rejko Krüger(Centre Hospitalier de Luxembourg), Albert C. Ludolph(Universität Ulm)
Cited by 90
Related Papers
MDS clinical diagnostic criteria for Parkinson's disease
|Movement Disorders|2015|7.4k
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
|New England Journal of Medicine|2009|2.1k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
Mortality after surgery in Europe: a 7 day cohort study
|The Lancet|2012|1.4k